Chula Vista, CANCT06712654Now EnrollingIRB Ready

Hyperphosphatemia Clinical Trial in Chula Vista, CA

Access cutting-edge hyperphosphatemia treatment through this clinical trial at a research site in Chula Vista. Study-provided care at no cost to qualified participants.

Sponsored by R1 Therapeutics

Quick Self-Assessment

See if you qualify for this Chula Vista location

Preparing your pre-screening questions…

Expert Care in Chula Vista

Access hyperphosphatemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hyperphosphatemia treatment provided free

Apply for This Chula Vista Location

Check if you qualify for this hyperphosphatemia clinical trial in Chula Vista, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chula Vista

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chula Vista site if eligible
  4. 4Begin participation

About This Hyperphosphatemia Study in Chula Vista

This study is being conducted to characterize the safety, tolerability, and efficacy of AP306 at fixed doses in adults with hyperphosphatemia receiving maintenance hemodialysis.

Sponsor: R1 Therapeutics

Who Can Participate

Inclusion Criteria

Signs a written informed consent form (ICF) and is willing to comply with all study requirements in the study
Receiving a stable hemodialysis (including hemodialysis, hemodiafiltration, and hemoadsorption) regimen, which is defined as a frequency of three times per week for at least 12 weeks before signing the ICF, and does not plan to change in the study
Who has a blood phosphate level within the study-required range
Who has a dialysis adequacy, assessed by single pooled Kt/V (SpKt/V, estimated with blood urea) ≥1.20, at screening or any documented value ≥1.20 within 12 weeks prior to signing the ICF
If the participant is receiving etelcalcetide, their doses must be unchanged for at least 4 weeks prior to signing the ICF
If the participant is receiving any of the following therapies, their doses are stable for at least 14 days prior to signing the ICF: phosphate-lowering products other than tenapanor or phosphate binders, active vitamin D and analogs, cinacalcet, calcitonin, and P-glycoprotein inhibitors
Agreement to use highly effective contraception for women of childbearing potentially and non-sterile sexually active males throughout the study and for 90 days after the final dose of study drug Important

Exclusion Criteria

Pregnant or breastfeeding
Scheduled for a living donor kidney transplant in the next 6 months, planned change to peritoneal dialysis or home hemodialysis in the study; planned relocation to another dialysis center in the study
Any history of a non-pharmacological parathyroid intervention within 6 months prior to the ICF sign off, or planned parathyroid intervention in the study
Blood calcium or blood intact parathyroid hormone abnormality
Adequate organ and bone marrow function
Acute hepatitis or significant chronic liver disease
Any clinically significant GI disorders within 4 weeks prior to signing the ICF; or any history of gastrectomy; or any GI tract surgery (excluding appendectomy and polypectomy), within 12 weeks of signing the ICF
Uncontrolled hypertension
Hospitalization for cardiac or cardiocerebrovascular disease within 24 weeks prior to signing the ICF
Significant abnormalities of QT interval and heart rhythm on an electrocardiograph (ECG) test
Any clinically significant active infection or infestation or any treatment with systemic antimicrobial treatment within 2 weeks prior to signing the ICF
History or presence of malignancy within 3 years prior to signing the ICF, except basal cell skin cancer, in-situ carcinoma of the cervix, and in-situ prostate cancer
Taking moderate or strong cytochrome P450 (CYP) 3A inhibitors within 2 weeks or 5 half-lives, whichever is longer, prior to signing the ICF (topical use is allowed)
Treatment with any investigational medication or medical device within 30 days prior to signing the ICF
Life expectancy less than 12 months

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chula Vista?

Yes, this clinical trial (NCT06712654) has an active research site in Chula Vista, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hyperphosphatemia Treatment Options in Chula Vista, CA

If you're searching for hyperphosphatemia treatment options in Chula Vista, CA, this clinical trial (NCT06712654) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chula Vista research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hyperphosphatemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hyperphosphatemia clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Chula Vista, CA

See all heart attack clinical trials recruiting in Chula Vista — not just this study.

Browse Heart Attack Trials in Chula Vista →

Browse More Trials by Condition

Heart Attack TrialsPulmonary Embolism TrialsPulmonary Hypertension TrialsRetinitis Pigmentosa TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Chula Vista?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chula Vista, CA